BIOMAT Database Logo BIOMAT Database Logo

Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor. 2019

Zhiwei Zhang, and Duqing Jiang, and Huan Yang, and Zhou He, and Xiangzhen Liu, and Wenxia Qin, and Linfang Li, and Chao Wang, and Yang Li, and He Li, and Hai Xu, and Huajun Jin, and Qijun Qian
Department of Biotherapy, The Eastern Hepatobiliary Surgery Hospital, Navy Medical University (Second Military Medical University), Shanghai, 201805, China.

Mesothelin (MSLN) is an attractive antigen for chimeric antigen receptor (CAR) T therapy and the epitope selection within MSLN is essential. In this study, we constructed two types of CARs targeting either region I of MSLN (meso1 CAR, also known as a membrane-distal region) or region III of MSLN (meso3 CAR, also known as a membrane-proximal region) using a modified piggyBac transposon system. We reported that, compared with meso1 CAR T cells, meso3 CAR T cells express higher levels of CD107α upon activation and produce increased levels of interleukin-2, TNF-α, and IFN-γ against multiple MSLN-expressing cancer cells in vitro. In a real-time cell analyzer system and a three-dimensional spheroid cancer cell model, we also demonstrated that meso3 CAR T cells display an enhanced killing effect compared with that of meso1 CAR T cells. More importantly, in a gastric cancer NSG mice model, meso3 CAR T cells mediated stronger antitumor responses than meso1 CAR T cells did. We further identified that meso3 CAR T cells can effectively inhibit the growth of large ovarian tumors in vivo. Collectively, our study provides evidences that meso3 CAR T-cell therapy performs as a better immunotherapy than meso1 CAR T-cell therapy in treating MSLN-positive solid tumors.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D005260 Female Females
D005434 Flow Cytometry Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake. Cytofluorometry, Flow,Cytometry, Flow,Flow Microfluorimetry,Fluorescence-Activated Cell Sorting,Microfluorometry, Flow,Cell Sorting, Fluorescence-Activated,Cell Sortings, Fluorescence-Activated,Cytofluorometries, Flow,Cytometries, Flow,Flow Cytofluorometries,Flow Cytofluorometry,Flow Cytometries,Flow Microfluorometries,Flow Microfluorometry,Fluorescence Activated Cell Sorting,Fluorescence-Activated Cell Sortings,Microfluorimetry, Flow,Microfluorometries, Flow,Sorting, Fluorescence-Activated Cell,Sortings, Fluorescence-Activated Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000090204 Mesothelin An ANTIGEN present on the surface of certain types of normal cells and overexpressed in several human tumors, including OVARIAN CANCER. CAK-1 Antigen,Megakaryocyte Potentiating Factor,Antigen, CAK-1,CAK 1 Antigen,Factor, Megakaryocyte Potentiating,Potentiating Factor, Megakaryocyte

Related Publications

Zhiwei Zhang, and Duqing Jiang, and Huan Yang, and Zhou He, and Xiangzhen Liu, and Wenxia Qin, and Linfang Li, and Chao Wang, and Yang Li, and He Li, and Hai Xu, and Huajun Jin, and Qijun Qian
The antitumor capacity of mesothelin-CAR-T cells in targeting solid tumors in mice.
March 2021, Molecular therapy oncolytics,
Zhiwei Zhang, and Duqing Jiang, and Huan Yang, and Zhou He, and Xiangzhen Liu, and Wenxia Qin, and Linfang Li, and Chao Wang, and Yang Li, and He Li, and Hai Xu, and Huajun Jin, and Qijun Qian
Targeting Macrophages with CAR T Cells Delays Solid Tumor Progression and Enhances Antitumor Immunity.
November 2022, Cancer immunology research,
Zhiwei Zhang, and Duqing Jiang, and Huan Yang, and Zhou He, and Xiangzhen Liu, and Wenxia Qin, and Linfang Li, and Chao Wang, and Yang Li, and He Li, and Hai Xu, and Huajun Jin, and Qijun Qian
Lenalidomide Enhances CAR-T Cell Activity Against Solid Tumor Cells.
January 2020, Cell transplantation,
Zhiwei Zhang, and Duqing Jiang, and Huan Yang, and Zhou He, and Xiangzhen Liu, and Wenxia Qin, and Linfang Li, and Chao Wang, and Yang Li, and He Li, and Hai Xu, and Huajun Jin, and Qijun Qian
Mesothelin-based CAR-T cells exhibit potent antitumor activity against ovarian cancer.
April 2024, Journal of translational medicine,
Zhiwei Zhang, and Duqing Jiang, and Huan Yang, and Zhou He, and Xiangzhen Liu, and Wenxia Qin, and Linfang Li, and Chao Wang, and Yang Li, and He Li, and Hai Xu, and Huajun Jin, and Qijun Qian
Tumor resistance to anti-mesothelin CAR-T cells caused by binding to shed mesothelin is overcome by targeting a juxtamembrane epitope.
January 2024, Proceedings of the National Academy of Sciences of the United States of America,
Zhiwei Zhang, and Duqing Jiang, and Huan Yang, and Zhou He, and Xiangzhen Liu, and Wenxia Qin, and Linfang Li, and Chao Wang, and Yang Li, and He Li, and Hai Xu, and Huajun Jin, and Qijun Qian
Targeting Mesothelin with Modified T Cells.
July 2015, Cancer discovery,
Zhiwei Zhang, and Duqing Jiang, and Huan Yang, and Zhou He, and Xiangzhen Liu, and Wenxia Qin, and Linfang Li, and Chao Wang, and Yang Li, and He Li, and Hai Xu, and Huajun Jin, and Qijun Qian
Deleting SUV39H1 in CAR-T cells epigenetically enhances the antitumor function.
May 2024, MedComm,
Zhiwei Zhang, and Duqing Jiang, and Huan Yang, and Zhou He, and Xiangzhen Liu, and Wenxia Qin, and Linfang Li, and Chao Wang, and Yang Li, and He Li, and Hai Xu, and Huajun Jin, and Qijun Qian
Probiotic-guided CAR-T cells for solid tumor targeting.
October 2023, Science (New York, N.Y.),
Zhiwei Zhang, and Duqing Jiang, and Huan Yang, and Zhou He, and Xiangzhen Liu, and Wenxia Qin, and Linfang Li, and Chao Wang, and Yang Li, and He Li, and Hai Xu, and Huajun Jin, and Qijun Qian
Human Hyaluronidase PH20 Potentiates the Antitumor Activities of Mesothelin-Specific CAR-T Cells Against Gastric Cancer.
January 2021, Frontiers in immunology,
Zhiwei Zhang, and Duqing Jiang, and Huan Yang, and Zhou He, and Xiangzhen Liu, and Wenxia Qin, and Linfang Li, and Chao Wang, and Yang Li, and He Li, and Hai Xu, and Huajun Jin, and Qijun Qian
Mesothelin-targeting T cells bearing a novel T cell receptor fusion construct (TRuC) exhibit potent antitumor efficacy against solid tumors.
January 2023, Oncoimmunology,
Copied contents to your clipboard!